Albireo

<!-- Name:DistributionId Value:1000795984 --> <!-- Name:NewsArchiveTags Value:Regulated_Info,Partnering,Corporate --> <!--…

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the grant of inducement…